BioSpace News Archive

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer; Gregory K. Chow, Executive Vice President and Chief Financial Officer; and Joti Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, will participate in the Cana

Enrollment in our Phase 2 clinical trial program for ELX-02 in cystic fibrosis has been resumed in Europe and Israel after being temporarily paused due to the COVID-19 pandemic U.S. FDA has granted orphan drug designation for ELX-02 for the treatment of cystic fibrosis Completing enrollment in our Phase 2 cystic fibrosis clinical trials and reporting top line data remain our highest priorities Preclinical studies continuing to advance in autosomal dominant polycystic kidney disease (ADP

PetVivo Holdings, Inc. an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office has allowed an important patent related to the Company’s proprietary biomaterial, which the company utilizes to produce its proprietary products.

— Completed last patient visits in Phase 3 PFIC and Phase 2 NASH Trials — — Enrolled first biliary atresia patients in second odevixibat pivotal study — — Completed two financing transactions to secure cash into beginning of 2022 — — Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today pro

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual investor events in August and September as follows: BTIG Virtual Biotechnology Conference: August 10 th – 11 th A BTIG analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the Com

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.

- Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses - AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to start - Zalifrelimab achieves responses in PD-1 failures (1CR, 3PRs); Ph2 expansion underway - Next-gen CTLA-4, PD-1 & iNKT activating therapy shows curative potential (AACR2020) - Renewably sourced QS-21 shows bio-equivalence; QS-21 enhances antibody titers in SARS-CoV-2 models - Pa

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a business update.

Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627),

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and upcoming events.